Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

INTRODUCTION: In the REVEL trial, ramucirumab plus docetaxel demonstrated significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared with placebo plus docetaxel for treatment of metastatic non-small cell lung cancer (NSCLC) that progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Garon, Edward B., Visseren-Grul, Carla, Rizzo, Maria Teresa, Puri, Tarun, Chenji, Suresh, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507469/
https://www.ncbi.nlm.nih.gov/pubmed/37731641
http://dx.doi.org/10.3389/fonc.2023.1247879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507469/
https://www.ncbi.nlm.nih.gov/pubmed/37731641
http://dx.doi.org/10.3389/fonc.2023.1247879

Ejemplares similares